Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad BiomedROCO:4188 -0.32%53 Days Payable is 40.54 as of Dec. 2025, which is 66% above its 10-year median of 24.36. GuruFocus rates ROCO:4188 with a GF Score™ of 53/100 and a GF Value™ of NT$9.10 (Fairly Valued). The stock has 4 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Amcad Biomed ranks worse than 74.43% on this metric.
The historical rank and industry rank for Amcad Biomed's Days Payable or its related term are showing as below:
ROCO:4188'
s Days Payable Range Over the Past 10 Years
Min: 14.8 Med: 24.36 Max: 255.5
Current: 41.54
During the past 13 years, Amcad Biomed's highest Days Payable was 255.50. The lowest was 14.80. And the median was 24.36.
ROCO:4188's Days Payable is ranked worse than 74.43% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs ROCO:4188: 41.54
Amcad Biomed's Days Payable
declined
from Dec. 2024 (44.95) to Dec. 2025 (40.54).
It may suggest that Amcad Biomedaccelerated paying its suppliers.
The historical data trend for Amcad Biomed's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4188 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Amcad Biomed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Days Payable distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Amcad Biomed's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amcad Biomed (ROCO:4188) has a Days Payable of 40.54 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Amcad Biomed and its competitors. This is 66% above median its historical median of 24.36. Over the past decade, Amcad Biomed's Days Payable has ranged from 14.80 to 255.50. According to the industry distribution chart, Amcad Biomed ranks #591 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 74.4%.
Is Amcad Biomed's Days Payable too high?
Amcad Biomed's current Days Payable of 40.54 is 66% above median its 10-year median of 24.36. Over the past 10 years, this metric has ranged from a low of 14.80 to a high of 255.50. The Medical Devices & Instruments industry median Days Payable is 67.97. Amcad Biomed's value of 40.54 is 40.4% below this industry median. Based on the distribution chart, Amcad Biomed ranks #591 out of 794 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Amcad Biomed has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #591 out of 794 companies for Days Payable. This places Amcad Biomed in the lower half of its industry. The industry median Days Payable is 67.97. Amcad Biomed's value of 40.54 is 40.4% below this benchmark. Historically, Amcad Biomed's own Days Payable has ranged from 14.80 to 255.50 over the past decade. While the company's 10-year median is 24.36 vs. the industry median of 67.97, Amcad Biomed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amcad Biomed's current Days Payable of 40.54 is 40.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current Days Payable is 40.54, which is 66% above median its own 10-year median of 24.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.10, compared to a current price of NT$9.45 — trading 3.8% above its estimated fair value. The current Days Payable is 40.54, which is 66% above median its 10-year median of 24.36 and 40.4% below the Medical Devices & Instruments industry median of 67.97. Amcad Biomed's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Days Payable is 40.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10.
GuruFocus considers Amcad Biomed to be Fairly Valued.
Key valuation signals for ROCO:4188:
Days Payable: 40.54 (66% above median its 10-year median of 24.36)
GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
Industry Position: 40.4% below the Medical Devices & Instruments median (#591 of 794)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score
Get the complete analysis for ROCO:4188
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
